MedTrace Logo

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00003792 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

MART-1 antigen

BIOLOGICAL

filgrastim

BIOLOGICAL

flu matrix peptide p58-66

BIOLOGICAL

gp100 antigen

BIOLOGICAL

recombinant MAGE-3.1 antigen

BIOLOGICAL

tyrosinase peptide

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Baylor Health Care System

    lead OTHER

Principal Investigators

  • Joseph W. Fay, MD · Baylor Health Care System

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-04-30
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003792 on ClinicalTrials.gov